SCHEMBL12335136

SCHEMBL12335136

Cc1nn(-c2ccc(Cl)cc2)c(N)c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.56
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
MAPT P10636 6/20 0.56
TDP1 Q9NUW8 5/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
MAPK1 P28482 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALOX12 P18054 1/20 0.56
HTT P42858 1/20 0.56
GAA P10253 1/20 0.49
HPGD P15428 3/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 2/20 0.44
ATM Q13315 1/20 0.42
OPRM1 P35372 1/20 0.42
LMNA P02545 4/20 0.42
KDM4E B2RXH2 2/20 0.42
APEX1 P27695 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28474950 0.85 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL12335137 0.85 ALDH1A1 (0.54) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL2461662 0.81 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL4070024 0.80 KMT2A (0.50) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL12335147 0.79 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL11700016 0.79 LMNA (0.61) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL10049725 0.78 NPC1 (0.49) SMN1; SMN2NPC1RAB9AMAPTTDP1
Water SCHEMBL11653913 0.76 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL12335140 0.76 CCNA2 (0.43) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL12335149 0.75 SMN1; SMN2 (0.39) SMN1; SMN2NPC1RAB9AMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed
WO-2011120026-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 SMN1; SMN2 4325/4885NPC1 3580/4885RAB9A 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.